Publications by authors named "S Kirthi"
Article Synopsis
- Hidradenitis suppurativa (HS) is a complex skin condition that's tough to treat, with adalimumab being the only approved therapy and only helping about 50% of patients.
- The study investigated differences in gene expression between affected (lesional) and unaffected (nonlesional) skin in HS patients before and after 12 weeks of adalimumab treatment, aiming to uncover potential biomarkers for treatment response.
- Findings suggest significant immune system involvement in HS, with certain genes indicating treatment response and disease severity, pointing towards the need for personalized treatment strategies targeting specific immune pathways.
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by the formation of nodules, abscesses, and fistulae at intertriginous sites. The skin-gut axis is an area of emerging research in inflammatory skin disease and is a potential contributory factor to the pathogenesis of HS. A total of 59 patients with HS provided fecal samples and nasal and skin swabs of affected sites for analysis.
View Article and Find Full Text PDFAn Update on Health-Related Quality of Life and Patient-Reported Outcomes in Hidradenitis Suppurativa.
Patient Relat Outcome Meas
February 2020
Hidradenitis suppurativa is a common inflammatory skin condition which causes recurrent abscesses, sinuses and scarring in the axillae, groin and inframammary areas. As well as causing significant physical distress due to pain and discharge, the condition impacts psychological well-being with markedly impaired quality of life. Patients suffer pain, embarrassment and psychological distress with impairment of their work and intimate relationships marking it as one of the most distressing dermatological conditions.
View Article and Find Full Text PDF